TEANECK, N.J., Jan. 25, 2024 /PRNewswire/ -- Cognizant (NASDAQ: CTSH) announced today an expanded agreement with Takeda (NYSE: TAK), a global biopharmaceutical company, to support the company's digital transformation strategy by reinforcing and supporting its technology efforts. Together, Takeda and Cognizant will embark on a new project to attract additional technology talent and help Takeda further expand its Innovation Capability Center operations.
"Cognizant's support has complemented our continuous innovation and digital growth," said Sanjay Patel, Takeda Global Head of DD&T Innovation Capability Solutions. "This continued relationship will enable Takeda to accelerate our digital transformation journey, modernize our operational model, and speed time to market."
Cognizant will help Takeda deliver digital capabilities as a service to the organization by identifying and hiring key talent to support the company's data, digital and technology ambitions. Supporting Takeda in not only transforming modern infrastructure and application management approaches, but also through a unique "build, operate, transform and transfer," or BOTT model, Cognizant will set up the team, initiate operations, automate functions, and transfer to Takeda.
"Cognizant's long-standing relationship with Takeda combined with our digital transformation expertise will ensure that we are able to support Takeda's aspiration to become one of the most trusted, science-driven, digital biopharmaceutical companies," said Surya Gummadi, Executive Vice President and President of Cognizant Americas. "We're excited to collaborate with Takeda to support digital engagement experiences through enhanced technology solutions."
About Cognizant
Cognizant (Nasdaq: CTSH) engineers modern businesses. We help our clients modernize technology, reimagine processes and transform experiences so they can stay ahead in our fast-changing world. Together, we're improving everyday life. See how at www.cognizant.com or @cognizant.
Cognizant Contacts:
U.S.: Jeff DeMarrais
This email address is being protected from spambots. You need JavaScript enabled to view it.
Europe/APAC: Christina Schneider
This email address is being protected from spambots. You need JavaScript enabled to view it.
India: Rashmi Vasisht
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$13.38 |
Daily Change: | 0.05 0.38 |
Daily Volume: | 1,486,539 |
Market Cap: | US$42.410B |
October 24, 2024 September 24, 2024 September 19, 2024 September 16, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB